TY  - JOUR
AU  - Longuespée, Rémi
AU  - Kunz, Julia
AU  - Fresnais, Margaux
AU  - Foerster, Kathrin I
AU  - Burhenne, Jürgen
AU  - Thomas, Michael
AU  - Kazdal, Daniel
AU  - Stenzinger, Albrecht
AU  - Christopoulos, Petros
AU  - Haefeli, Walter E
TI  - Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report.
JO  - British journal of clinical pharmacology
VL  - 90
IS  - 1
SN  - 0306-5251
CY  - Oxford
PB  - Wiley-Blackwell
M1  - DKFZ-2023-02225
SP  - 344-349
PY  - 2024
N1  - Case report / 2024 Jan;90(1):344-349 / #EA:B350#
AB  - Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
KW  - LC-MS/MS (Other)
KW  - MALDI-MS/MS (Other)
KW  - non-small cell lung cancer (Other)
KW  - osimertinib (Other)
KW  - short bowel syndrome (Other)
KW  - therapeutic drug monitoring (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37815301
DO  - DOI:10.1111/bcp.15924
UR  - https://inrepo02.dkfz.de/record/285101
ER  -